Guardant Health - GH Stock Forecast, Price & News

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Guardant Health Price Performance

NASDAQ:GH traded down $1.75 during mid-day trading on Wednesday, hitting $51.42. 835,610 shares of the stock traded hands, compared to its average volume of 1,262,891. The company has a quick ratio of 5.83, a current ratio of 6.18 and a debt-to-equity ratio of 3.56. Guardant Health has a 12-month low of $27.65 and a 12-month high of $133.82. The company has a market cap of $5.26 billion, a PE ratio of -9.56 and a beta of 0.81. The business's 50-day moving average price is $46.33 and its 200 day moving average price is $54.00.

Guardant Health (NASDAQ:GH - Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($2.25) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by ($1.00). Guardant Health had a negative return on equity of 99.90% and a negative net margin of 135.03%. The company had revenue of $109.14 million during the quarter, compared to analysts' expectations of $105.14 million. During the same period in the prior year, the firm earned ($0.96) EPS. Guardant Health's quarterly revenue was up 18.5% on a year-over-year basis. On average, analysts expect that Guardant Health will post -5.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GH shares. OTR Global downgraded shares of Guardant Health to a "positive" rating in a research note on Monday, August 1st. The Goldman Sachs Group reduced their target price on shares of Guardant Health from $90.00 to $80.00 and set a "buy" rating for the company in a research note on Monday, August 8th. Piper Sandler started coverage on shares of Guardant Health in a research note on Thursday, June 2nd. They issued an "overweight" rating and a $65.00 target price for the company. Citigroup reduced their target price on shares of Guardant Health from $120.00 to $100.00 in a research note on Friday, May 6th. Finally, Morgan Stanley reduced their target price on shares of Guardant Health from $85.00 to $80.00 and set an "overweight" rating for the company in a research note on Monday, August 8th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health presently has a consensus rating of "Buy" and a consensus target price of $119.00.

Insiders Place Their Bets

In other Guardant Health news, SVP Amelia Merrill sold 4,500 shares of the business's stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $53.38, for a total value of $240,210.00. Following the completion of the transaction, the senior vice president now owns 24,708 shares of the company's stock, valued at approximately $1,318,913.04. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 5.90% of the company's stock.